Advertisement

Breast Cancer in Elderly Women

  • Monica Morrow
  • Lisa S. Wiechmann
Chapter

Abstract

Breast cancer is the most common malignancy in American women aside from skin cancer, and the second leading cause of cancer death, exceeded only by lung cancer. It is estimated that there were 182,460 new breast cancer cases diagnosed in the United States in 2008, and 40,480 deaths. In addition to invasive breast cancer, carcinoma in situ (CIS), the earliest form of breast cancer, accounted for about 67,770 new cases in 2008 [1].

Keywords

Breast Cancer Sentinel Node Endocrine Therapy Sentinel Node Biopsy Elderly Woman 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    American Cancer Society Cancer Statistics 2008. www.cancer.org. Accessed 16 February 2009
  2. 2.
    Bergman L, Dekker G, van Leeuwen FE, Huisman SJ, van Dam FS, van Dongen JA (1991) The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 67(9):2227–2234PubMedCrossRefGoogle Scholar
  3. 3.
    Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl):2208–2214PubMedCrossRefGoogle Scholar
  4. 4.
    MacMahon B, Cole P, Brown J (1973) Etiology of human breast cancer: a review. J Natl Cancer Inst 50(1):21–42PubMedGoogle Scholar
  5. 5.
    Waterhouse J, Muis C, Correa P (eds) (1976) Cancer incidence in 5 continents. Lyon International Agency for Research on Cancer, Lyon, AIRC Scientific Publications; No. 3Google Scholar
  6. 6.
    Yancik R, Ries LG, Yates JW (1989) Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 63(5):976–981PubMedCrossRefGoogle Scholar
  7. 7.
    Chu KC, Tarone RE, Kessler LG et al (1996) Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88(21):1571–1579PubMedCrossRefGoogle Scholar
  8. 8.
    Howe HL, Wu X, Ries LA et al (2006) Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107(8):1711–1742PubMedCrossRefGoogle Scholar
  9. 9.
    Ravdin PM, Cronin KA, Howlander N, Chelbowski RT, Berry DA (2006) A decrease in breast cancer incidence in the United States in 2003. In: 29th annual San Antonio breast cancer symposium, San Antonio, TXGoogle Scholar
  10. 10.
    Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28PubMedCrossRefGoogle Scholar
  11. 11.
    Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792PubMedCrossRefGoogle Scholar
  12. 12.
    Du XL, Fox EE, Lai D (2008) Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol 31(2):105–116PubMedCrossRefGoogle Scholar
  13. 13.
    Rosen PP, Lesser ML, Kinne DW (1985) Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years and older than 75 years. J Surg Oncol 28(2):90–96PubMedCrossRefGoogle Scholar
  14. 14.
    Schaefer G, Rosen PP, Lesser ML, Kinne DW, Beattie EJ Jr (1984) Breast carcinoma in elderly women: pathology, prognosis, and survival. Pathol Annu 19(Pt 1):195–219PubMedGoogle Scholar
  15. 15.
    Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S (1993) Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 85(20):1644–1656PubMedCrossRefGoogle Scholar
  16. 16.
    Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL (1995) Efficacy of screening mammography. A meta-analysis. JAMA 273(2):149–154PubMedCrossRefGoogle Scholar
  17. 17.
    Tabar L, Fagerberg G, Duffy SW, Day NE (1989) The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43(2):107–114PubMedCrossRefGoogle Scholar
  18. 18.
    Van Dijck JA, Verbeek AL, Beex LV et al (1997) Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer 70(2):164–168PubMedCrossRefGoogle Scholar
  19. 19.
    Jonsson H, Tornberg S, Nystrom L, Lenner P (2003) Service screening with mammography of women aged 70–74 years in Sweden. Effects on breast cancer mortality. Cancer Detect Prev 27(5):360–369PubMedCrossRefGoogle Scholar
  20. 20.
    Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J (2000) Is screening mammography effective in elderly women? Am J Med 108(2):112–119PubMedCrossRefGoogle Scholar
  21. 21.
    Taplin SH, Ichikawa L, Yood MU et al (2004) Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst 96(20):1518–1527PubMedCrossRefGoogle Scholar
  22. 22.
    Mandelblatt JS, Wheat ME, Monane M, Moshief RD, Hollenberg JP, Tang J (1992) Breast cancer screening for elderly women with and without comorbid conditions. A decision analysis model. Ann Intern Med 116(9):722–730PubMedGoogle Scholar
  23. 23.
    Moskowitz M (1986) Breast cancer: age-specific growth rates and screening strategies. Radiology 161(1):37–41PubMedGoogle Scholar
  24. 24.
    Boer R, de Koning HJ, van Oortmarssen GJ, van der Maas PJ (1995) In search of the best upper age limit for breast cancer screening. Eur J Cancer 31A(12):2040–2043PubMedCrossRefGoogle Scholar
  25. 25.
    Fracheboud J, Groenewoud JH, Boer R et al (2006) Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 118(8):2020–2025PubMedCrossRefGoogle Scholar
  26. 26.
    U.S. Preventative Services Task Force (1989) Guide to Clinical Preventative Services: an assessment of the effectiveness of 169 interventions. Williams & Wilkins, BaltimoreGoogle Scholar
  27. 27.
    (1990) Screening mammography: a missed clinical opportunity? Results of the NCI Breast Cancer Screening Consortium and National Health Interview Survey Studies. JAMA 264(1):54–58Google Scholar
  28. 28.
    Leathar DS, Roberts MM (1985) Older women’s attitudes towards breast disease, self examination, and screening facilities: implications for communication. Br Med J (Clin Res Ed) 290(6469):668–670CrossRefGoogle Scholar
  29. 29.
    Fox SA, Siu AL, Stein JA (1994) The importance of physician communication on breast cancer screening of older women. Arch Intern Med 154(18):2058–2068PubMedCrossRefGoogle Scholar
  30. 30.
    Caplan LS (2001) To screen or not to screen: the issue of breast cancer screening in older women. Public Health Rev 29(2–4):231–240PubMedGoogle Scholar
  31. 31.
    Field TS, Doubeni C, Fox MP et al (2008) Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med 23(2):158–163PubMedCrossRefGoogle Scholar
  32. 32.
    Schneiderman MA, Axtell LM (1979) Deaths among female patients with carcinoma of the breast treated by a surgical procedure only. Surg Gynecol Obstet 148(2):193–195PubMedGoogle Scholar
  33. 33.
    Davis SJ, Karrer FW, Moor BJ, Rose SG, Eakins G (1985) Characteristics of breast cancer in women over 80 years of age. Am J Surg 150(6):655–658PubMedCrossRefGoogle Scholar
  34. 34.
    Hunt KE, Fry DE, Bland KI (1980) Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg 140(3):339–342PubMedCrossRefGoogle Scholar
  35. 35.
    Kesseler HJ, Seton JZ (1978) The treatment of operable breast cancer in the elderly female. Am J Surg 135(5):664–666PubMedCrossRefGoogle Scholar
  36. 36.
    Singletary SE, Shallenberger R, Guinee VF (1993) Breast cancer in the elderly. Ann Surg 218(5):667–671PubMedCrossRefGoogle Scholar
  37. 37.
    Oakley N, Dennison AR, Shorthouse AJ (1996) A prospective audit of simple mastectomy under local anaesthesia. Eur J Surg Oncol 22(2):134–136PubMedCrossRefGoogle Scholar
  38. 38.
    Carlson GW (2005) Total mastectomy under local anesthesia: the tumescent technique. Breast J 11(2):100–102PubMedCrossRefGoogle Scholar
  39. 39.
    Clark RM, Wilkinson RH, Miceli PN, MacDonald WD (1987) Breast cancer. Experiences with conservation therapy. Am J Clin Oncol 10(6):461–468PubMedCrossRefGoogle Scholar
  40. 40.
    Fourquet A, Campana F, Zafrani B et al (1989) Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 17(4):719–725PubMedCrossRefGoogle Scholar
  41. 41.
    Veronesi U, Salvadori B, Luini A et al (1990) Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 211(3):250–259PubMedGoogle Scholar
  42. 42.
    Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedCrossRefGoogle Scholar
  43. 43.
    American College of Radiology (2007) Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. J Am Coll Surg 205(2):362–376CrossRefGoogle Scholar
  44. 44.
    Hiotis K, Ye W, Sposto R, Skinner KA (2005) Predictors of breast conservation therapy: size is not all that matters. Cancer 103(5):892–899PubMedCrossRefGoogle Scholar
  45. 45.
    Mandelblatt JS, Hadley J, Kerner JF et al (2000) Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 89(3):561–573PubMedCrossRefGoogle Scholar
  46. 46.
    Wyld L, Garg DK, Kumar ID, Brown H, Reed MW (2004) Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 90(8):1486–1491PubMedCrossRefGoogle Scholar
  47. 47.
    Bleicher RJ, Abrahamse P, Hawley ST, Katz SJ, Morrow M (2008) The influence of age on the breast surgery decision-making process. Ann Surg Oncol 15(3):854–862PubMedCrossRefGoogle Scholar
  48. 48.
    Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMedGoogle Scholar
  49. 49.
    Bartelink H, Horiot JC, Poortmans PM et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25(22):3259–3265PubMedCrossRefGoogle Scholar
  50. 50.
    Hughes KS, Schnaper LA, Berry D et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977PubMedCrossRefGoogle Scholar
  51. 51.
    Kirova YM, Campana F, Savignoni A et al (2009) Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys 75(1):76–81PubMedCrossRefGoogle Scholar
  52. 52.
    Whelan T, Pignol JP, Julian J (2007) Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer. Breast Cancer 106:S6Google Scholar
  53. 53.
    Wyckoff J, Greenberg H, Sanderson R, Wallach P, Balducci L (1994) Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc 42(2):150–152PubMedGoogle Scholar
  54. 54.
    Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888PubMedCrossRefGoogle Scholar
  55. 55.
    Posther KE, McCall LM, Blumencranz PW et al (2005) Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg 242(4):593–599, discussion 599–602PubMedGoogle Scholar
  56. 56.
    Giuliano AE, Jones RC, Brennan M, Statman R (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15(6):2345–2350PubMedGoogle Scholar
  57. 57.
    Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349(9069):1864–1867PubMedCrossRefGoogle Scholar
  58. 58.
    Gennari R, Rotmensz N, Perego E, dos Santos G, Veronesi U (2004) Sentinel node biopsy in elderly breast cancer patients. Surg Oncol 13(4):193–196PubMedCrossRefGoogle Scholar
  59. 59.
    Wilke LG, McCall LM, Posther KE et al (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13(4):491–500PubMedCrossRefGoogle Scholar
  60. 60.
    Rudenstam CM, Zahrieh D, International Breast Cancer Study Group et al (2006) Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol 24(3):337–344PubMedCrossRefGoogle Scholar
  61. 61.
    DiFronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE (2000) Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer? Ann Surg Oncol 7(6):406–410PubMedCrossRefGoogle Scholar
  62. 62.
    Hieken TJ, Nettnin S, Velasco JM (2004) The value of sentinel lymph node biopsy in elderly breast cancer patients. Am J Surg 188(4):440–442PubMedCrossRefGoogle Scholar
  63. 63.
    Lucci A, McCall LM, Beitsch PD et al (2007) Surgical ­complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663PubMedCrossRefGoogle Scholar
  64. 64.
    Schijven MP, Vingerhoets AJ, Rutten HJ et al (2003) Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29(4):341–350PubMedCrossRefGoogle Scholar
  65. 65.
    Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553PubMedCrossRefGoogle Scholar
  66. 66.
    Fisher B, Redmond C, Fisher ER et al (1985) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312(11):674–681PubMedCrossRefGoogle Scholar
  67. 67.
    Halverson KJ, Taylor ME, Perez CA et al (1993) Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 26(4):593–599PubMedCrossRefGoogle Scholar
  68. 68.
    Britton RC, Nelson PA (1962) Causes and treatment of post-mastectomy lymphedema of the arm. Report of 114 cases. JAMA 180:95–102PubMedCrossRefGoogle Scholar
  69. 69.
    Larson D, Weinstein M, Goldberg I et al (1986) Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12(9):1575–1582PubMedCrossRefGoogle Scholar
  70. 70.
    McLaughlin SA, Wright MJ, Morris KT et al (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219PubMedCrossRefGoogle Scholar
  71. 71.
    Pezner RD, Patterson MP, Hill LR et al (1986) Arm lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys 12(12):2079–2083PubMedCrossRefGoogle Scholar
  72. 72.
    Hladiuk M, Huchcroft S, Temple W, Schnurr BE (1992) Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 50(1):47–52PubMedCrossRefGoogle Scholar
  73. 73.
    Spruit PH, Siesling S, Elferink MA, Vonk EJ, Hoekstra CJ (2007) Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol 2:40PubMedCrossRefGoogle Scholar
  74. 74.
    Hind D, Wyld L, Reed MW (2007) Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer 96(7):1025–1029PubMedCrossRefGoogle Scholar
  75. 75.
    Fentiman IS, Christiaens MR, Paridaens R et al (2003) Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39(3):309–316PubMedCrossRefGoogle Scholar
  76. 76.
    Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M (2004) Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 91(6):699–704PubMedCrossRefGoogle Scholar
  77. 77.
    Mustacchi G, Ceccherini R, Milani S et al (2003) Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14(3):414–420PubMedCrossRefGoogle Scholar
  78. 78.
    Willsher PC, Robertson JF, Chan SY, Jackson L, Blamey RW (1997) Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 33(1):45–49PubMedCrossRefGoogle Scholar
  79. 79.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRefGoogle Scholar
  80. 80.
    McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ, The Scottish Cancer Trials Breast Group (1995) Cardiac and ­vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 311:977–980CrossRefGoogle Scholar
  81. 81.
    Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751–757PubMedCrossRefGoogle Scholar
  82. 82.
    Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109PubMedCrossRefGoogle Scholar
  83. 83.
    Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486–492PubMedCrossRefGoogle Scholar
  84. 84.
    Forbes JF, Cuzick J, Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53PubMedCrossRefGoogle Scholar
  85. 85.
    Crivellari D, Sun Z, Coates AS et al (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26(12):1972–1979PubMedCrossRefGoogle Scholar
  86. 86.
    Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293(9):1073–1081PubMedCrossRefGoogle Scholar
  87. 87.
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24(18):2750–2756PubMedCrossRefGoogle Scholar
  88. 88.
    Muss HB, Berry DL, Cirrincione C, Theodoulou M, Mauer A, Cohen H (2008) Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. 2008 ASCO Annual Meeting. J Clin Oncol 26(8 Supp):5–20, abstract 507Google Scholar
  89. 89.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672PubMedCrossRefGoogle Scholar
  90. 90.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684PubMedCrossRefGoogle Scholar
  91. 91.
    Slamon D, Eiermann W, Robert N, et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients (abstract 52). In: San Antonio breast cancer symposium, San Antonio, TXGoogle Scholar
  92. 92.
    Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH (1996) Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 124(6):577–584PubMedGoogle Scholar
  93. 93.
    Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96(17):1311–1321PubMedCrossRefGoogle Scholar
  94. 94.
    Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL (2001) The consequence of undertreating breast cancer in the elderly. J Am Coll Surg 192(6):698–707PubMedCrossRefGoogle Scholar
  95. 95.
    Enger SM, Thwin SS, Buist DS et al (2006) Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 24(27):4377–4383PubMedCrossRefGoogle Scholar
  96. 96.
    Owusu C, Lash TL, Silliman RA (2007) Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J 13(4):374–382PubMedCrossRefGoogle Scholar
  97. 97.
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS (2003) Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 138(2):90–97PubMedGoogle Scholar
  98. 98.
    Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48(1):6–29PubMedCrossRefGoogle Scholar
  99. 99.
    Allen C, Cox EB, Manton KG, Cohen HJ (1986) Breast cancer in the elderly. Current patterns of care. J Am Geriatr Soc 34(9):637–642PubMedGoogle Scholar
  100. 100.
    Schottenfeld D, Robbins GF (1971) Breast cancer in elderly women. Geriatrics 26(3):121–131PubMedGoogle Scholar
  101. 101.
    Berg JW, Robbins GF (1961) Modified mastectomy for older, poor risk patients. Surg Gynecol Obstet 113:631–634PubMedGoogle Scholar
  102. 102.
    Kraft RO, Block GE (1962) Mammary carcinoma in the aged patient. Ann Surg 156:981–985PubMedCrossRefGoogle Scholar
  103. 103.
    Muss HB (2007) Adjuvant treatment of elderly breast cancer patients. Breast 16(Suppl 2):S159–S165. In: Proceedings of the 10th international conference on primary therapy of early breast cancer. St. Gallen, Switzerland, 14–17, March 2007PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Breast Service, Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations